Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Lancet Oncology

• Publication date

  2012-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(12)70007-4PMID 22326922
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Cancer statistics, 2011

  2011cited by this paper
• High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Current status of immunological therapies for prostate cancer

  2010cited by this paper
• Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

  2010cited by this paper
• Prostate cancer as a model for tumour immunotherapy

  2010cited by this paper
• Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

  2010cited by this paper
• Improved Endpoints for Cancer Immunotherapy Trials

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

  2010cited by this paper
• Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy

  2010cited by this paper
• Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

  2009cited by this paper
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

  2008cited by this paper
• Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer

  2008cited by this paper
• Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

  2008cited by this paper
• Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

  2007cited by this paper
• A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

  2007cited by this paper
• Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.

  2007cited by this paper
• Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma.

  2007cited by this paper
• Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer

  2007cited by this paper
• Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.

  2006cited by this paper
• Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naïve Prostate Cancer

  2006cited by this paper
• Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

  2005cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Mechanisms of androgen-refractory prostate cancer.

  2004cited by this paper
• Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

  1999cited by this paper
• The emerging role of CTLA-4 as an immune attenuator.

  1997cited by this paper
• Enhancement of Antitumor Immunity by CTLA-4 Blockade

  1996cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper

• Innovative immunotherapies for prostate cancer: understanding the synergies between checkpoint inhibition, CAR T-cell therapy, and next-generation therapeutic modalities

  2026cites this paper
• Recent advancements in therapeutic biomarkers, associated challenges and considerations to overcome these challenges in prostate cancer (Review)

  2025cites this paper
• Mapping a New Blueprint of Multimodal Immunotherapy Against Prostate Cancer: Breakthroughs, Barriers, and Bold Frontiers

  2025cites this paper
• Myeloid-Derived Suppressor Cells (MDSCs) at the Crossroad of Senescence and Cancer

  2025cites this paper
• Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors

  2025cites this paper
• Immunotherapy Vaccines for Prostate Cancer Treatment

  2024cites this paper
• Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers

  2024cites this paper
• Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management.

  2024cites this paper
• Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti‐tumour T‐cell activation – IRE‐IMMUNO study

  2024cites this paper
• Frequency and clinical characteristics of hypophysitis and hypopituitarism in patients undergoing immunotherapy – A systematic review

  2023cites this paper
• Vaccines as treatments for prostate cancer

  2023cites this paper
• Cancer-on-chip models for metastasis: importance of the tumor microenvironment.

  2023cites this paper
• Targeted Radiation and Immune Therapies—Advances and Opportunities for the Treatment of Prostate Cancer

  2023cites this paper
• Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Influence on Soluble and Membrane Bound ICOS in Combination with Immune Checkpoint Blockade.

  2023cites this paper
• Combination Immunotherapy in Prostate Cancer

  2022cites this paper
• The Cellular and Molecular Immunotherapy in Prostate Cancer

  2022cites this paper
• Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination with Checkpoint Inhibitors and Beyond.

  2022cites this paper
• Suspected immune checkpoint inhibitor‐induced pulmonary sarcoid reaction in metastatic renal cell carcinoma

  2022cites this paper
• Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors

  2022cites this paper
• Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.

  2022cites this paper
• Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment

  2022cites this paper
• Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer.

  2022cites this paper
• Prostate cancer immunotherapy

  2022cites this paper
• Changing Landscape of Cancer Vaccines—Novel Proteomics Platform for New Antigen Compositions

  2022cites this paper
• Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches

  2022cites this paper
• Electrical Stimulation for Immune Modulation in Cancer Treatments

  2022cites this paper
• Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.

  2022cites this paper
• Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy

  2021cites this paper
• Pulmonary adverse events due to immune checkpoint inhibitors: A literature review.

  2021cites this paper
• Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances

  2021cites this paper
• Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens

  2021cites this paper
• Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer

  2021influential citation
• Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces

  2021cites this paper
• The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries

  2021cites this paper
• Clinical Experience with CTLA-4 Blockade for Cancer Immunotherapy: From the Monospecific Monoclonal Antibody Ipilimumab to Probodies and Bispecific Molecules Targeting The Tumor Microenvironment.

  2021cites this paper
• Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach

  2021cites this paper
• Research and application of hydrostatic high pressure in tumor vaccines

  2021cites this paper
• Dendritic Cells Pulsed with Cytokine-Adjuvanted Tumor Membrane Vesicles Inhibit Tumor Growth in HER2-Positive and Triple Negative Breast Cancer Models

  2021influential citation
• Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer

  2021cites this paper
• Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?

  2021cites this paper
• Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment

  2021cites this paper
• Prognostic value of immune checkpoint molecules in breast cancer

  2020cites this paper
• Opportunities for Conventional and In Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review

  2020cites this paper
• Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians.

  2020cites this paper
• Cancer Immunotherapy Confers a Global Benefit

  2020cites this paper
• A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.

  2020cites this paper
• Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer

  2020cites this paper
• Hepatobiliary Adverse Events.

  2020cites this paper
• The Roles of CD4+ T-Cells in Tumor Immunity

  2020cites this paper
• Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review

  2020influential citation
• Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model

  2020cites this paper
• Future Challenges in Cancer Resistance to Immunotherapy

  2020cites this paper
• Immunotherapie van kanker

  2020cites this paper
• Hepatotoxicity induced by PD-1 inhibitors in cancer treatment

  2020cites this paper
• Autoimmune Hypophysitis

  2020cites this paper
• Future Challenges in Cancer Resistance to Immunotherapy.

  2020cites this paper
• Synergistic Therapeutic Effects of Probiotic Lactobacillus casei TD-2 Consumption on GM-CSF-Induced Immune Responses in a Murine Model of Cervical Cancer

  2020cites this paper
• Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy

  2020cites this paper
• Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies.

  2020cites this paper
• Multivalent, Soluble Nano-Self Peptides Increase Phagocytosis of Antibody-Opsonized Targets while Suppressing "Self" Signaling.

  2020cites this paper
• TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts

  2020cites this paper
• Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes.

  2020cites this paper
• Genomic analysis of the prognostic value of colony-stimulating factors (CSFs) and colony-stimulating factor receptors (CSFRs) across 24 solid cancer types

  2020cites this paper
• Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  2020cites this paper
• Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.

  2020cites this paper
• Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer

  2020cites this paper
• Overcoming Cancer Tolerance with Immune Checkpoint Blockade

  2020cites this paper
• Immunotherapy in prostate cancer: current state and future perspectives

  2020cites this paper
• Immune checkpoint inhibitor-associated hypercalcaemia.

  2020cites this paper
• Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis

  2019cites this paper
• Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy.

  2019cites this paper
• Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment

  2019cites this paper
• Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis

  2019cites this paper
• Urologic Malignancies

  2019cites this paper
• New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation.

  2019cites this paper
• Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment

  2019cites this paper
• Emerging therapeutic agents for genitourinary cancers

  2019cites this paper
• 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.

  2019cites this paper
• Immune checkpoint inhibitors and the development of granulomatous reactions.

  2019cites this paper
• Past, Current, and Future of Immunotherapies for Prostate Cancer

  2019cites this paper
• Tumor Cell-Based Vaccine Generated With High Hydrostatic Pressure Synergizes With Radiotherapy by Generating a Favorable Anti-tumor Immune Microenvironment

  2019cites this paper
• Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.

  2019cites this paper
• General Discussion and Future Perspectives

  2019cites this paper
• Cancer Vaccines

  2019cites this paper
• Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies

  2019cites this paper
• Future Research Goals in Immunotherapy.

  2019cites this paper
• The evolving landscape of immunotherapy in advanced prostate cancer.

  2019cites this paper
• Immune checkpoint inhibitor-induced sarcoidosis-like granulomas

  2019cites this paper
• Modulating inflammation for cancer therapy

  2019cites this paper
• Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings.

  2019cites this paper
• Drug-Induced Injury, Polyps, Congenital, and Miscellaneous Disorders

  2019cites this paper
• Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings

  2019cites this paper
• Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators

  2019cites this paper
• Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises

  2019cites this paper
• Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment

  2018cites this paper
• The research progress and clinical application of personalized peptide vaccines in castration-resistant prostate cancer

  2018cites this paper
• Immune Therapy for Castration-Resistant Prostate Cancer

  2018cites this paper
• Chapter 7 Immune Checkpoint Blockade : Subjugation of the Masses

  2018cites this paper
• Immune Checkpoint Inhibitors-Induced Hepatitis.

  2018cites this paper
• Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients

  2018cites this paper